New Drugs of 2012, Part 2

MARCH 19, 2013
Michael A. Mancano, PharmD
New Drugs of 2012, Part 2

Michael A. Mancano, PharmD
Clinical Professor of Pharmacy Practice
Chair, Department of Pharmacy Practice
Temple University School of Pharmacy
Philadelphia, Pennsylvania
Clinical Consultant, Pennsylvania Hospital
Department of Pharmacy
Philadelphia, Pennsylvania

The following contributors have no relevant financial relationships with commercial interests to disclose.
Michael A. Mancano, PharmD
Pharmacy Times Office of Continuing Professional Education Planning Staff
Judy V. Lum, MPA; and Elena Beyzarov, PharmD
Pharmacy Times Editorial Staff
Jennifer Whartenby and David Allikas
PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Objectives
Upon completion of this educational activity, participants should be able to:
  1. Discuss the clinical indications of the new drugs approved by the FDA in 2012.
  2. Explain the various mechanisms of action of the drugs discussed within this activity.
  3. Recognize the clinically relevant drug interactions and adverse reactions for the drugs reviewed in this activity.
  4. Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.
Target audience:  Pharmacists
Type of activity:  Knowledge
Release date:  March 10, 2013
Expiration date:  March 10, 2015
Estimated time to complete activity:  2 hours
Fee:  This lesson is free online

Click here to view this activity.


The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


Pharmacy Times Strategic Alliance

Conference Coverage
News from the year's biggest meetings

Pharmacist Education
Clinical features with downloadable PDFs


Personalize the information you receive by selecting targeted content and special offers.